---
title: "VK2735 in Chronic weight management: VK2735-102 part 1 subcutaneous maintenance"
description: "Formulary evidence on VK2735 in Chronic weight management: VK2735-102 part 1 subcutaneous maintenance. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 63 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence/vk2735-102-part-1-subcutaneous-maintenance"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: VK2735-102 part 1 subcutaneous maintenance

<a id="heading-3.1.7"></a>

## 3.1.7 VK2735-102 Part 1 Subcutaneous Maintenance

<a id="heading-3.1.7.1"></a>

### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

#### Safety, tolerability, and pharmacokinetic objectives with exploratory weight endpoints

> “The objectives of the study were to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of VK2735 under these various dosing regimens. Exploratory endpoints assessed change in body weight from baseline, as well as change in body weight from Week 21 to the end of the study at Week 33.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.1-2"></a>

#### Brief summary in the ClinicalTrials.gov record

> “The goal of this Phase 1, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VK2735 in adults who are obese (BMI ≥ 30 kg/m2) without comorbidities.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.1-3"></a>

#### Evaluation of the transition from weekly to monthly or every-other-week dosing

> “Designed to evaluate transition from Weekly (QW) to SC monthly (QM) or every other week (QOW) dosing regimens”
> “Endpoints: Safety, tolerability, PK, weight change”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.1-4"></a>

#### Purpose stated at study initiation

> “The trial being announced today is intended to explore the feasibility of various VK2735 maintenance dosing regimens utilizing either the oral tablet or the subcutaneous formulation to sustain the initial weight loss achieved following weekly subcutaneous dosing.”

Source: [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="heading-3.1.7.2"></a>

### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

#### Initiation in October 2025 and completion of enrollment in January 2026

> “SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of an exploratory maintenance dosing study of VK2735”

Source: [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

> “SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735”

Source: [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity)

<a id="topic-3.1.7.2-2"></a>

#### Top-line results announced in September 2026

> “SAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's maintenance study of VK2735”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.2-3"></a>

#### Study dates and United States sites in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Study start (actual) | “2025-11-18” |
| Primary completion (estimated) | “2027-05” |
| Study completion (estimated) | “2027-07” |
| First posted | “2026-09-24” |
| Site 1 | “Viking Clinical Site #001” |
| Site 1 city | “Lake Forest” |
| Site 2 | “Viking Clinical Site #002” |
| Site 2 city | “Miami” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.7.3"></a>

### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

#### Design as reported with the top-line results: 21-week induction and subcutaneous maintenance

> “The maintenance dosing study was a randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2) and otherwise healthy. All participants received initial weekly subcutaneous doses of VK2735 or placebo for 21 weeks. Following Week 21, participants were transitioned to a range of VK2735 maintenance dosing options including monthly, every other week, or weekly subcutaneous injections, or placebo.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.3-2"></a>

#### Part 1 as one part of a two-part range-finding study

> “In the third quarter the company reported positive results from Part 1 of a two-part range-finding study.”
> “Part 1 of the maintenance study was focused on subcutaneous dosing. The novel design incorporated multiple parts – a 21-week induction period, a 12-week maintenance period evaluating monthly or every-other-week dosing, and a 33-week dosing period utilizing a 17.5 mg weekly dose. A total of 180 subjects were randomized across 11 treatment groups.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.3-3"></a>

#### Study periods in the investor presentation

> “6-week screening”
> “Weekly SC titration (21 weekly doses)”
> “12-week maintenance”
> “5-week follow-up”
> “Part 1: Subcutaneous (SC) maintenance dosing”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.3-4"></a>

#### Placebo comparator for the maintenance period

> “Compares favorably to 61% maintenance effect for participants transitioned from 17.5 mg QW to placebo; p<0.01 all cohorts”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.3-5"></a>

#### Two study parts and 18 treatment groups in the ClinicalTrials.gov record

> “Approximately 270 participants will be enrolled across two study parts: Part A and Part B. A total of 18 treatment groups are planned. Part A contains Groups 1 to 12, and Part B contains Groups 13 to 18. Part A will be completed prior to the enrollment of Part B.”
> “Participants in Part A will be randomized equally across 12 treatment arms to receive one of 11 VK2735 dose regimens or a matching placebo regimen.”
> “Each study part is comprised of treatment periods 1 and 2, lasting 21 weeks and 12 weeks, respectively. Study participants may receive a different dosing frequency and/or route of administration between the two periods.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.3-6"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Official title | “A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VK2735 Administration in Adults Who Are Obese (BMI ≥ 30 kg/m2) Without Comorbidities” |
| Other study ID | “VK2735-102” |
| Phase | “Phase 1” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Double” |
| Primary purpose | “Treatment” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.3-7"></a>

#### Original design announced at initiation: 19-week induction with oral and subcutaneous maintenance options

> “Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated”
> “The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2) and otherwise healthy. All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants will be transitioned to a range of VK2735 maintenance dosing options including monthly subcutaneous doses, daily oral doses, weekly oral doses, or placebo.”
> “Exploratory endpoints will assess change in body weight from baseline, as well as change in body weight from Week 19 to the end of the study at Week 31.”

Source: [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

<a id="topic-3.1.7.3-8"></a>

#### Design stated at completion of enrollment: 19-week induction with oral and subcutaneous maintenance options

> “Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens”
> “All enrolled participants receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants are transitioned to a range of VK2735 maintenance dosing regimens including weekly, every other week, or monthly subcutaneous dosing, as well as daily oral dosing, weekly oral dosing, or placebo.”

Source: [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity)

<a id="topic-3.1.7.3-9"></a>

#### Design described in the annual report filed in February 2026

> “All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Following Week 19, participants will be transitioned to a range of VK2735 maintenance dosing options including monthly subcutaneous doses, daily oral doses, weekly oral doses, or placebo.”

Source: [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm)

<a id="heading-3.1.7.4"></a>

### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

#### Obesity without other comorbidities

> “Subjects were required to have a BMI ≥30 kg/m2 but no other comorbidities.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.4-2"></a>

#### Inclusion criteria in the ClinicalTrials.gov record (both study parts)

> “Must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the study Investigator.”
> “BMI ≥ 30 kg/m2.”
> “Willing to comply with contraceptive requirements.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.4-3"></a>

#### Exclusion criteria in the ClinicalTrials.gov record (both study parts)

> “Current or past diagnosis of diabetes mellitus (including type 1 and type 2, except gestational diabetes).”
> “Have a personal or family history of medullary thyroid carcinoma (MTC) or have multiple endocrine neoplasia syndrome type 2 (MEN-2).”
> “History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.4-4"></a>

#### Age range in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Minimum age | “18 Years” |
| Maximum age | “60 Years” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.7.5"></a>

### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

#### Two-week titration steps to induction doses of 15.0 to 22.5 mg

> “Participants in this study were randomized to receive weekly doses of VK2735 or placebo for 21 weeks. Starting in Week 3, VK2735 doses were escalated every two weeks until final doses of 15.0 mg, 17.5 mg, 20.0 mg, or 22.5 mg were achieved.”
> “Subjects treated with VK2735 were titrated to final doses as indicated: Week 1 = 1.25 mg; Week 2 = 2.5 mg; Week 3-4 = 5.0 mg; Week 5-6 = 7.5 mg; Week 7-8 = 10.0 mg; Week 9-10 = 12.5 mg; Week 11-12 = 15.0 mg; Week 13-14 = 17.5 mg; Week 15-16 = 20.0 mg; Week 17 = 22.5 mg.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.5-2"></a>

#### Every-other-week maintenance regimens

> “At Week 21 subjects were transitioned to maintenance dosing as indicated and treated for 12 weeks: 17.5 mg weekly to 5.0 mg QOW; 15 mg weekly to 7.5 mg QOW; 17.5 mg weekly to 10 mg QOW.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.5-3"></a>

#### Monthly maintenance regimens

> “At Week 21 subjects were transitioned to maintenance dosing as indicated and treated for 12 weeks: 17.5 mg weekly to 10.0 mg QM; 17.5 mg weekly to 15.0 mg QM; 17.5 mg weekly to 17.5 mg QM; 20.0 mg weekly to 20.0 mg QM; 22.5 mg once weekly to 22.5 mg QM.”
> “During the maintenance dosing period, participants were randomized to a range of monthly (every four weeks) and every-other-week dosing regimens to evaluate the effect of less frequent dosing on weight maintenance.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.5-4"></a>

#### Exploratory control arm continuing 17.5 mg weekly

> “An exploratory control arm in the study evaluated weight change in a cohort of participants who continued receiving weekly VK2735 doses of 17.5 mg (n=13).”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.5-5"></a>

#### Part A treatment arms in the ClinicalTrials.gov record

| Arm label | Registry description |
| --- | --- |
| “Placebo” | “Placebo Subcutaneously (SC) weekly” |
| “VK2735 Dose Level 2” | “VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly” |
| “VK2735 Dose Level 3” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously weekly” |
| “VK2735 Dose Level 4” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week” |
| “VK2735 Dose Level 5” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 6” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 7” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 8” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 9” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously monthly” |
| “VK2735 Dose Level 10” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week” |
| “VK2735 Dose Level 11” | “VK2735 subcutaneously weekly followed by VK2735 subcutaneously every other week” |
| “VK2735 Dose Level 12” | “VK2735 subcutaneously weekly followed by Placebo subcutaneously weekly” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="heading-3.1.7.6"></a>

### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

#### 3.1.7.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

##### Registered primary and secondary outcome measures

| Outcome | Measure | Description | Time frame |
| --- | --- | --- | --- |
| Primary | “Evaluate the Safety and Tolerability VK2735” | “Incidence of treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)” | “33 weeks” |
| Secondary | “Evaluate the Pharmacokinetic profile of VK23735” | “Pharmacokinetic profile of SC VK2735 by measuring peak plasma concentration (Cmax) after weekly, every other week, or monthly administration” | “38 weeks” |

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.6.1-2"></a>

##### Body weight as an exploratory endpoint

> “Exploratory endpoints assessed change in body weight from baseline, as well as change in body weight from Week 21 to the end of the study at Week 33.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.6.1-3"></a>

##### Percentage of week 21 weight loss maintained at week 33

> “Mean percentage of Week 21 weight loss maintained at Week 33 (%)”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.6.1-4"></a>

##### Company view of the weight-loss threshold for cardiometabolic benefit

> “The cardiometabolic benefits of maintaining 75% or more of a patient's weight loss are becoming clearer, and these results demonstrating robust maintenance with reduced and less frequent doses are supportive of maintaining people within that margin through either monthly or every-other-week administration.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.7"></a>

### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

#### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

##### Planned enrollment at initiation and enrollment at completion

> “The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2) and otherwise healthy.”

Source: [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity)

> “The trial enrolled approximately 180 adults with BMI ≥30 kg/m2 but who are otherwise healthy.”

Source: [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity)

<a id="topic-3.1.7.7.1-2"></a>

##### Participants randomized

> “A total of 180 subjects were randomized across 11 treatment groups.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.7.1-3"></a>

##### Estimated enrollment across both parts in the ClinicalTrials.gov record

> “Approximately 270 participants will be enrolled across two study parts: Part A and Part B.”

Source: [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.7.1-4"></a>

##### Participants analyzed in the induction efficacy population

| Group | Participants analyzed at week 21 |
| --- | --- |
| Placebo | “(n=15)” |
| VK2735 15 mg weekly | “(n=14)” |
| VK2735 17.5 mg weekly | “(n=118)” |
| VK2735 20 mg weekly | “(n=15)” |
| VK2735 22.5 mg weekly | “(n=14)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.7.1-5"></a>

##### Participants in the induction safety population and with an observed week 21 weight

> “Placebo (n=15) VK2735 Combined (n=166) VK2735 15 mg QW (n=15) VK2735 17.5 mg QW (n=121) VK2735 20 mg QW (n=15) VK2735 22.5 mg QW (n=15)”
> “VK2735, Combined n=143”
> “Observed values for subjects with weight measurement at W21 visit.”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.7.1-6"></a>

##### Participants analyzed in the maintenance period

| Group | Efficacy population | Safety population |
| --- | --- | --- |
| Placebo after 17.5 mg weekly | “(n=27)” | “(n=27)” |
| VK2735 combined every other week | “(n=37)” | “(n=37)” |
| VK2735 combined monthly | “QM (n=65)” | “QM (n=66)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.7.2"></a>

#### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

##### Induction efficacy population

> “Efficacy population, includes all randomized patients who received at least one dose of study drug and had a valid baseline and post-baseline body weight assessment.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.7.2-2"></a>

##### Maintenance efficacy population

> “Efficacy population, includes all randomized patients who received at least one dose of study drug on or after Week 21 and had a valid post-Week 21 body weight assessment.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.7.2-3"></a>

##### Induction and maintenance safety populations

> “Safety population, includes all randomized subjects who received at least one dose of study drug.”

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

> “Safety population, includes all randomized subjects who received at least one dose of study drug on or after Week 21.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.7.2-4"></a>

##### Statistical methods for weight endpoints

> “Least squares mean.”
> “Two-sided t-test using mixed model for repeated measures.”
> “Excludes subject with maintenance effect >2.5x standard deviation from cohort mean; inclusion of this subject results in 99% weight loss maintenance for this cohort.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.8"></a>

### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

#### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

##### Discontinuations during the 21-week induction period

| Outcome | Placebo (n=15) | VK2735 combined (n=166) | 15 mg weekly (n=15) | 17.5 mg weekly (n=121) | 20 mg weekly (n=15) | 22.5 mg weekly (n=15) |
| --- | --- | --- | --- | --- | --- | --- |
| Discontinued treatment early | “0 (0%)” | “22 (13%)” | “2 (13%)” | “15 (12%)” | “1 (7%)” | “4 (27%)” |
| Discontinued treatment due to adverse event | “0 (0%)” | “1 (1%)” | “0 (0%)” | “1 (1%)” | “0 (0%)” | “0 (0%)” |

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.8.1-2"></a>

##### Discontinuations during the every-other-week maintenance period

| Outcome | Placebo (n=27) | VK2735 combined (n=37) | 5.0 mg (n=12) | 7.5 mg (n=13) | 10.0 mg (n=12) |
| --- | --- | --- | --- | --- | --- |
| Discontinued treatment early | “0 (0 %)” | “1 (3 %)” | “0 (0 %)” | “0 (0 %)” | “1 (8 %)” |
| Discontinued treatment due to adverse event | “0 (0 %)” | “1 (3 %)” | “0 (0 %)” | “0 (0 %)” | “1 (8 %)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.1-3"></a>

##### Discontinuations during the monthly maintenance period

| Outcome | Placebo (n=27) | VK2735 combined (n=66) | 10 mg (n=16) | 15 mg (n=14) | 17.5 mg (n=11) | 20 mg (n=14) | 22.5 mg (n=11) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Discontinued treatment early | “0 (0 %)” | “3 (5 %)” | “0 (0 %)” | “1 (7 %)” | “1 (9 %)” | “1 (7 %)” | “0 (0 %)” |
| Discontinued treatment due to adverse event | “0 (0 %)” | “1 (2 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “1 (7 %)” | “0 (0 %)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.8.2"></a>

#### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

##### Mean baseline body weight by induction dose

| Group | Mean baseline body weight |
| --- | --- |
| Placebo (n=15) | “100.0 kg” |
| VK2735 15 mg weekly (n=14) | “108.4 kg” |
| VK2735 17.5 mg weekly (n=118) | “95.9 kg” |
| VK2735 20 mg weekly (n=15) | “101.9 kg” |
| VK2735 22.5 mg weekly (n=14) | “103.0 kg” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.2-2"></a>

##### Baseline body mass index requirement

> “All enrolled participants were required to have baseline BMI ≥30 kg/m2.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.8.3"></a>

#### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

##### Induction weight loss at week 21

> “Weight loss after 21 weeks of dosing ranged from approximately 16% to 19% compared with approximately 0% for placebo (p<0.0001 vs. baseline and placebo, all cohorts). Weight loss during the induction period was progressive in each cohort, with no evidence of plateau through 21 weeks of weekly dosing.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-2"></a>

##### Change in body weight after 21 weeks of weekly dosing

| Measure | Placebo (n=15) | 15 mg weekly (n=14) | 17.5 mg weekly (n=118) | 20 mg weekly (n=15) | 22.5 mg weekly (n=14) |
| --- | --- | --- | --- | --- | --- |
| Mean change from baseline body weight | “-0.1 kg” | “-17.0 kg” | “-17.0 kg” | “-18.6 kg” | “-17.2 kg” |
| Mean percent change from baseline | “-0.1 %” | “-16.3 %” | “-17.8 %” | “-18.7 %” | “-17.1 %” |
| Placebo-adjusted mean percent change from baseline | “-” | “-16.2 %” | “-17.7 %” | “-18.6 %” | “-17.0 %” |
| p-value vs. placebo | “-” | “<0.0001” | “<0.0001” | “<0.0001” | “<0.0001” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-3"></a>

##### Weight-loss thresholds at week 21

> “At 21 weeks in the combined VK2735 treatment groups, the proportion of participants demonstrating 5%, 10%, 15%, and 20% weight loss were 98%, 90%, 65%, and 32% as compared with 13%, 0%, 0%, and 0% for placebo (p<0.01 vs. placebo for each).”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-4"></a>

##### Separation from placebo from week 4

> “All doses clearly separated from placebo starting at Week 4, with p-values at each dosing level less than 0.0001 compared with placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.8.3-5"></a>

##### Weight loss maintained after transition to every-other-week dosing

> “Subjects randomized to every-other-week dosing regimens maintained up to 97% of mean weight loss achieved in the weekly induction period. This compares with 61% mean weight loss maintenance among subjects randomized to placebo (p<0.0001 vs. placebo). Separation from placebo was noted as early as four weeks following transition from weekly dosing.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-6"></a>

##### Percentage of week 21 weight loss maintained at week 33 with every-other-week dosing

| Measure | Placebo (n=27) | Combined every other week (n=37) | 17.5 mg weekly to 5.0 mg every other week (n=12) | 15.0 mg weekly to 7.5 mg every other week (n=13) | 17.5 mg weekly to 10.0 mg every other week (n=12) |
| --- | --- | --- | --- | --- | --- |
| Mean percentage of week 21 weight loss maintained at week 33 | “61 %” | “90 %” | “83 %” | “90 %” | “97 %” |
| p-value vs. placebo | “-” | “p<0.0001” | “0.004” | “<0.0001” | “<0.0001” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-7"></a>

##### Weight loss maintained after transition to monthly dosing

> “Participants randomized to monthly dosing regimens successfully maintained up to 90% of mean weight loss achieved during the induction period, compared with 61% mean weight loss maintenance among subjects randomized to placebo (p=0.0002 vs. placebo). As with the transition to every-other-week dosing, separation from placebo was noted as early as four weeks following transition from weekly dosing.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-8"></a>

##### Percentage of week 21 weight loss maintained at week 33 with monthly dosing

| Measure | Placebo (n=27) | Combined monthly (n=65) | 17.5 mg weekly to 10 mg monthly (n=16) | 17.5 mg weekly to 15 mg monthly (n=14) | 17.5 mg weekly to 17.5 mg monthly (n=11) | 20 mg weekly to 20 mg monthly (n=14) | 22.5 mg weekly to 22.5 mg monthly (n=10) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Mean percentage of week 21 weight loss maintained at week 33 | “61 %” | “85 %” | “82 %” | “84 %” | “90 %” | “86 %” | “85 %” |
| p-value vs. placebo | “-” | “<0.0001” | “0.0016” | “0.0012” | “0.0002” | “0.0005” | “0.0024” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-9"></a>

##### Ranges of weight loss retained by regimen

> “Among subjects dosed every-other-week, mean weight loss retained at Week 33 ranged from 83% to 97%, compared with 61% among subjects transitioned from 17.5 mg weekly to placebo, with p-values less than 0.01 for each cohort vs. placebo. Among subjects transitioned to monthly dosing, mean weight loss retained at Week 33 ranged from 82% to 90%, compared with 61% for placebo, with p-values less than 0.01 for each cohort vs. placebo.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.8.3-10"></a>

##### Continued 17.5 mg weekly dosing through week 33

> “This cohort demonstrated mean weight loss of 21.7% from baseline (Week 0) (p<0.0001 vs. baseline), compared with 0.3% weight gain for placebo (p<0.0001 vs. placebo). Weight loss in this cohort was progressive through 33 weeks of treatment with no plateau observed.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.3-11"></a>

##### Company cross-trial comparison at week 33

> “Looking across the current treatment landscape, the currently approved GLP-1 GIP agonists have demonstrated approximately 14% placebo-adjusted weight loss at week 33. In addition, the most advanced triple agonist in development with glucagon activity demonstrated approximately 17% placebo-adjusted weight loss at the 33-week time point. These are, of course, published data using different titration methods and not head-to-head study data.”

Source: [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)

<a id="heading-3.1.7.8.4"></a>

#### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.7.8.5"></a>

#### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

##### Tolerability during the induction period

> “One subject (1%) in the induction period discontinued VK2735 treatment due to an adverse event. The most common adverse events were gastrointestinal (GI) in nature, characterized as mild, and in-line with those expected from activation of the GLP-1 receptor. Despite the accelerated 2-week titration schedule utilized in this study, rates of common GI adverse events such as nausea, vomiting, constipation, and diarrhea were similar to those reported in the prior Phase 2 study, which utilized 3-week titration steps.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.5-2"></a>

##### Adverse events and gastrointestinal adverse events through week 21

| Event | Placebo (n=15) | VK2735 combined (n=166) | 15 mg weekly (n=15) | 17.5 mg weekly (n=121) | 20 mg weekly (n=15) | 22.5 mg weekly (n=15) |
| --- | --- | --- | --- | --- | --- | --- |
| Treatment-emergent adverse events | “7 (47%)” | “116 (70%)” | “11 (73%)” | “83 (69%)” | “10 (67%)” | “12 (80%)” |
| Nausea, mild | “1 (7%)” | “67 (40%)” | “6 (40%)” | “47 (39%)” | “3 (20%)” | “11 (73%)” |
| Nausea, moderate | “0 (0%)” | “3 (2%)” | “0 (0%)” | “2 (2%)” | “0 (0%)” | “1 (7%)” |
| Vomiting | “1 (7%)” | “45 (27%)” | “6 (40%)” | “32 (26%)” | “2 (13%)” | “5 (33%)” |
| Diarrhea | “3 (20%)” | “33 (20%)” | “3 (20%)” | “24 (20%)” | “3 (20%)” | “3 (20%)” |
| Constipation | “1 (7%)” | “18 (11%)” | “1 (7%)” | “12 (10%)” | “1 (7%)” | “4 (27%)” |

Source: [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf)

<a id="topic-3.1.7.8.5-3"></a>

##### Tolerability during the maintenance period

> “Rates of GI-related adverse events such as vomiting, nausea, diarrhea, and constipation were not meaningfully different from placebo over the 12-week maintenance window. Discontinuation rates, including discontinuations due to adverse events (AEs), were low during both the maintenance and induction portions of the trial.”

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

> “These data suggest that despite a gap of up to four weeks between doses, these participants did not resensitize to GI adverse events such as nausea or vomiting.”

Source: [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update)

<a id="topic-3.1.7.8.5-4"></a>

##### Adverse events after transition to every-other-week dosing

| Event | Placebo (n=27) | VK2735 combined (n=37) | 5.0 mg (n=12) | 7.5 mg (n=13) | 10.0 mg (n=12) |
| --- | --- | --- | --- | --- | --- |
| Treatment-emergent adverse events | “14 (52 %)” | “14 (38 %)” | “4 (33 %)” | “5 (39 %)” | “5 (42 %)” |
| Nausea, mild | “0 (0 %)” | “2 (5 %)” | “1 (8 %)” | “1 (8 %)” | “0 (0 %)” |
| Vomiting | “2 (7 %)” | “1 (3 %)” | “0 (0 %)” | “0 (0 %)” | “1 (8 %)” |
| Diarrhea | “1 (4 %)” | “2 (5 %)” | “0 (0 %)” | “2 (15 %)” | “0 (0 %)” |
| Constipation | “1 (4 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="topic-3.1.7.8.5-5"></a>

##### Adverse events after transition to monthly dosing

| Event | Placebo (n=27) | VK2735 combined (n=66) | 10 mg (n=16) | 15 mg (n=14) | 17.5 mg (n=11) | 20 mg (n=14) | 22.5 mg (n=11) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment-emergent adverse events | “14 (52 %)” | “32 (49 %)” | “7 (44 %)” | “7 (50 %)” | “5 (46 %)” | “7 (50 %)” | “6 (55 %)” |
| Nausea, mild | “0 (0 %)” | “3 (4.5 %)” | “1 (6 %)” | “2 (14 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |
| Vomiting | “2 (7 %)” | “5 (8 %)” | “2 (13 %)” | “1 (7 %)” | “1 (9 %)” | “1 (7 %)” | “0 (0 %)” |
| Diarrhea | “1 (4 %)” | “3 (5 %)” | “1 (6 %)” | “0 (0 %)” | “0 (0 %)” | “2 (14 %)” | “0 (0 %)” |
| Constipation | “1 (4 %)” | “2 (3 %)” | “1 (6 %)” | “1 (7 %)” | “0 (0 %)” | “0 (0 %)” | “0 (0 %)” |

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens)

<a id="heading-3.1.7.9"></a>

### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

#### Summary: study limitations

Part 1 of the VK2735-102 study was a phase 1 trial in which 180 otherwise healthy adults with a body mass index of at least 30 kg/m2 and no diabetes were randomized across 11 treatment groups; the registry age range was 18 to 60 years. The primary endpoint was the incidence of treatment-emergent adverse events, and all body weight endpoints were exploratory. The induction placebo group had 15 participants, while 118 of the 176 participants in the induction efficacy population received 17.5 mg weekly. Each maintenance regimen had 10 to 16 participants in the efficacy population, the maintenance period lasted 12 weeks, and the maintenance placebo group (27 participants) consisted of participants switched from 17.5 mg weekly to placebo at week 21. The result for the 22.5 mg monthly cohort excludes one participant with a “maintenance effect >2.5x standard deviation from cohort mean”. During induction, 22 of 166 VK2735-treated participants (13%) discontinued treatment early, including 4 of 15 (27%) at 22.5 mg weekly, compared with 0 of 15 receiving placebo; the induction safety population (181 participants) is 1 larger than the reported number randomized (180). The design changed after initiation: the releases of October 2025 and January 2026 and the Form 10-K of February 2026 described a 19-week induction, maintenance options that included “daily oral doses” and “weekly oral doses”, and an end of study at week 31, whereas the reported Part 1 used a 21-week induction, subcutaneous maintenance only, and an end of study at week 33. The ClinicalTrials.gov record was first posted on 2026-09-24, after enrollment was complete and 2 days after the top-line release, and it lists an estimated enrollment of 270 for both parts. Results are available only in a press release, investor presentations, and a call transcript, with no peer-reviewed publication and no results posted to the registry, and no health-related quality of life outcomes were reported.

Source: [Viking Therapeutics maintenance study topline release (2026)](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens); [Viking Therapeutics maintenance study presentation (2026)](https://ir.vikingtherapeutics.com/image/Maintenance+Study+Presentation.pdf); [Viking Therapeutics third quarter 2026 results release (2026)](https://ir.vikingtherapeutics.com/2026-10-28-Viking-Therapeutics-Reports-Third-Quarter-2026-Financial-Results-and-Provides-Corporate-Update); [Viking Therapeutics maintenance study initiation release (2025)](https://ir.vikingtherapeutics.com/2025-10-21-Viking-Therapeutics-Announces-Initiation-of-VK2735-Maintenance-Dosing-Clinical-Trial-in-Patients-with-Obesity); [Viking Therapeutics maintenance study enrollment release (2026)](https://ir.vikingtherapeutics.com/2026-01-08-Viking-Therapeutics-Announces-Completion-of-Enrollment-in-Maintenance-Dosing-Clinical-Trial-of-VK2735-in-Obesity); [Viking Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm); [ClinicalTrials.gov NCT07838740](https://clinicaltrials.gov/study/NCT07838740)

<a id="topic-3.1.7.9-2"></a>

#### Small cohort size acknowledged by the company

> “As far as the 22.5 mg, I think it is a very small cohort, so probably the most likely explanation there is that the N was small.”

Source: [Viking Therapeutics maintenance study topline call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/758817-study-result/)

<a id="topic-3.1.7.9-3"></a>

#### Longer extension data preferred for a regulatory submission

> “It's more likely that we would use the VANQUISH extension studies because that will be a longer and larger data set versus the first maintenance study.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
